September 28, 2022 10:37 AM EDT

Gamida Cell prices its follow-on public offering at $20M; Rallybio touts Phase Ib data for monoclonal antibody

While Gamida Cell is still charging its way toward approval for its therapies with new CEO Abigail Jenkins in place, it’s looking to garner …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Gami­da Cell prices its fol­low-on pub­lic of­fer­ing at $20M; Rally­bio touts Phase Ib da­ta for mon­o­clon­al an­ti­body